C4XD.L Stock - C4X Discovery Holdings plc
Unlock GoAI Insights for C4XD.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $1.71M | $2.70M | $5.64M | N/A | N/A |
| Gross Profit | $1.67M | $2.57M | $5.55M | $-485,000 | $-191,000 |
| Gross Margin | 97.8% | 95.2% | 98.4% | N/A | N/A |
| Operating Income | $-13,414,000 | $-10,522,000 | $-5,893,000 | $-9,566,000 | $-13,637,000 |
| Net Income | $-11,111,000 | $-8,160,000 | $-3,844,000 | $-7,789,000 | $-10,912,000 |
| Net Margin | -649.8% | -302.3% | -68.1% | N/A | N/A |
| EPS | $-0.04 | $-0.04 | $-0.02 | $-0.08 | $-0.19 |
C4X Discovery Holdings plc operates as a drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality. The company's product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation and autoimmune diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. It has partnerships with Sanofi, GEN-COVID, LifeArc, Indivior PLC, Phoremost, AstraZeneca UK Limited, and Evotec SE. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was incorporated in 2007 and is based in Manchester, the United Kingdom.
Visit WebsiteEarnings History & Surprises
C4XD.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 25, 2025 | — | — | — | — |
Q4 2024 | Dec 12, 2024 | — | — | — | — |
Q2 2024 | Apr 15, 2024 | — | $0.07 | — | — |
Q4 2023 | Dec 14, 2023 | $0.04 | $-0.03 | -175.5% | ✗ MISS |
Q2 2023 | Apr 26, 2023 | $-0.02 | $-0.02 | +22.5% | ✓ BEAT |
Q4 2022 | Nov 28, 2022 | $-0.01 | $-0.02 | -44.5% | ✗ MISS |
Q1 2022 | Jan 31, 2022 | $-0.02 | $-0.02 | +13.9% | ✓ BEAT |
Q3 2021 | Jul 31, 2021 | $0.00 | $-0.00 | -130.0% | ✗ MISS |
Q1 2021 | Jan 31, 2021 | $-0.03 | $-0.02 | +21.9% | ✓ BEAT |
Q3 2020 | Jul 31, 2020 | $-0.02 | $-0.03 | -80.1% | ✗ MISS |
Q1 2020 | Jan 31, 2020 | $-0.06 | $-0.05 | +9.5% | ✓ BEAT |
Q3 2019 | Jul 31, 2019 | — | $-0.10 | — | — |
Q1 2019 | Jan 31, 2019 | — | $-0.05 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.01 | — | — |
Q1 2018 | Jan 31, 2018 | — | $-0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.08 | — | — |
Q1 2017 | Jan 31, 2017 | — | $-0.04 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.08 | — | — |
Q1 2016 | Jan 31, 2016 | — | $-0.08 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-0.05 | — | — |
Latest News
Frequently Asked Questions about C4XD.L
What is C4XD.L's current stock price?
What is the analyst price target for C4XD.L?
What sector is C4X Discovery Holdings plc in?
What is C4XD.L's market cap?
Does C4XD.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to C4XD.L for comparison